Scientists test 'Double-Punch' immune cell therapy for tough blood cancers
NCT ID NCT05797233
Summary
This early-stage trial is testing a new type of CAR-T cell therapy designed to fight B-cell cancers like leukemia and lymphoma. The therapy modifies a patient's own immune T-cells to hunt and kill cancer cells by targeting two proteins (CD19 and CD20) on the cancer's surface. The study aims to find a safe dose for adults whose cancers have not been controlled by standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.